SABS vs MTRX Comparison

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Matrix Service Co provides engineering, fabrication, construction, and maintenance services supporting critical energy infrastructure and industrial markets. Its reportable segments are Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities, with Storage and Terminal Solutions generating the maximum revenue. This segment provides integrated EPC, repair, maintenance, and fabrication services for bulk liquid, cryogenic, and refrigerated storage and terminal facilities supporting traditional and emerging energy markets, including LNG, NGLs, petroleum products, chemicals, hydrogen, and ammonia, and manufactures specialty tank products. The majority of revenue is generated from the United States.